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A B S T R A C T
Objective: Multisystem iron poisoning is a major concern for long-term beta-thalassemia management.
Quantitative MRI-based techniques routinely show iron overload in heart, liver, endocrine glands and kidneys.
However, data on the brain are conflicting and monitoring of brain iron content is still matter of debate.
Methods: This 3T-MRI study applied a well validated high-resolution whole-brain quantitative MRI assessment
of iron content on 47 transfusion-dependent (mean-age: 36.9 ± 10.3 years, 63% females), 23 non-transfusion
dependent (mean-age: 29.2 ± 11.7 years, 56% females) and 57 healthy controls (mean-age: 33.9 ± 10.8 years,
65% females). Clinical data, Wechsler Adult Intelligence Scale scores and treatment regimens were recorded.
Beside whole-brain R2* analyses, regional R2*-values were extracted in putamen, globus pallidum, caudate
nucleus, thalamus and red nucleus; hippocampal volumes were also determined.
Results: Regional analyses yielded no significant differences between patients and controls, except in those
treated with deferiprone that showed lower R2*-values (p<0.05). Whole-brain analyses of R2*-maps revealed
strong age-R2* correlations (r2=0.51) in both groups and clusters of significantly increased R2*-values in beta-
thalassemia patients in the hippocampal formations and around the Luschka foramina; transfusion treatment
was associated with additional R2* increase in dorsal thalami. Hippocampal formation R2*-values did not
correlate with hippocampal volume; hippocampal volume did not differ between patients and controls. All re-
gions with increased R2*-values shared a strict anatomical contiguity with choroid plexuses suggesting a
blooming effect as the likely cause of R2* increase, in agreement with the available histopathologic literature
evidence.
Conclusion: According to our MRI findings and the available histopathologic literature evidence, concerns about
neural tissue iron overload in beta-thalassemia appear to be unjustified.
Introduction
Beta-thalassemia is a group of disorders caused by defective
production in beta-globin chains of hemoglobin, determining in-
effective erythropoiesis and microcytic anemia. The clinical phenotype
may vary greatly, thus requiring different types of care (Taher et al.,
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2018). The most severe form necessitates regular red blood cell trans-
fusions since the first years of life, while less severe forms may require
only occasional transfusions to face specific needs (e.g. during growth,
pregnancy or infections). While chronic anemia has achieved a good
control, at least where regular blood treatment is available, multisystem
involvement during the disease course occurs in almost all clinical
phenotypes because of systemic iron overload. The latter derives not
only from blood transfusion regimens but also from ineffective ery-
thropoiesis and increased gastrointestinal absorption, approximately 3
to 4 times greater than normal (Gardenghi et al., 2007). Each unit of
packed red blood cells contains approximately 200–250mg of iron (Á
et al., 2013) that largely overwhelms iron excretion capabilities (about
1mg/day) (Hunt et al., 2009) thus heavily concurring to persistently
high serum ferritin levels and multiorgan iron poisoning. Detecting iron
overload before overt organ damage allows a tailored chelation therapy
that helps to prevent organ failure or to revert early stages of iron-
related comorbidities (Anderson et al., 2004; Casale et al., 2014). Iron
monitoring is therefore crucial and usually rely on serum ferritin levels,
albeit these do not strictly correlate with tissue iron accumulation
(Aubart et al., 2016) in all organs. Direct measurement of iron stores is
only achievable through biopsy (e.g. liver biopsy), which cannot be
easily or repeatedly obtained for all organs (Ambu et al., 1995).
In the last two decades, quantitative MRI-based techniques have
allowed a precious in vivo non-invasive assessment of iron stores at
least for the most vulnerable organs (e.g. heart and liver). Indeed,
cardiac and liver T2* MRIs are now part of the routine management of
beta-thalassemia (Viprakasit et al., 2018). In recent years, the same
approach has been applied for endocrine glands, pituitary gland in-
cluded, and kidneys, helping to better characterize the iron-related
multisystem involvement (Bozdağ et al., 2017; Hashemieh et al., 2017;
Kosaryan et al., 2017).
Recent methodological advances have provided in vivo brain iron
content quantification via MRI mapping of the effective transverse re-
laxation rate (R2*=1/T2*[s−1]). This approach has been previously
validated for the brain with histological measurements
(Langkammer et al., 2010) and can be boosted using multiple three-
dimensional pulse sequences in reasonable scan time (Deoni et al.,
2005; Dick et al., 2012; Helms and Dechent, 2009; Sereno et al., 2013)
at clinical magnetic field strength (1.5–3.0 Tesla). Particularly, a multi-
parametric mapping acquisition protocol based on multi-echo 3D Fast
Low-Angle Shot (FLASH) sequences has been recently well validated to
obtain high resolution (≤1mm) whole brain maps of iron content via
voxel-based quantification of R2* parameters (Helms et al., 2008, 2008;
Weiskopf et al., 2011, 2014). The multi-parametric mapping protocol
provides standardized metrics with a high degree of reproducibility
(Weiskopf et al., 2013) and enables the extraction of iron deposition
patterns in large cohorts without the need of a priori localization and
tailoring of the regions of interest (Whitaker et al., 2016;
Callaghan et al., 2014).
In the attempt to solve the question if brain iron overload is real in
beta-thalassemia, here we performed a voxel-based whole-brain quan-
titative MRI study of iron content involving 70 beta-thalassemia pa-
tients (recruited from 4 major centers in Southern Italy) and 57 age and
sex matched controls to compare iron (R2*) brain maps between
transfusion dependent/non transfusion dependent beta-thalassemia




Transfusion-dependent and non-transfusion-dependent patients
were recruited from 4 referral centers for beta-thalassemia. Inclusion
criteria were: diagnosis of beta-thalassemia and age >16 years.
Patients were considered with Transfusion Dependent Thalassemia
(TDT) if on a regular transfusion regimen over the last 10 years; those
who were not regularly transfused and had not received any transfusion
during the last 48 weeks before the enrolment were enrolled as subjects
with Non Transfusion Dependent Thalassemia (NTDT).
Exclusion criteria were contraindications to MRI, history of neuro-
logic disease, head trauma or neurosurgery. Controls were healthy
volunteers aged >16 years mostly recruited among patients’ relatives
and entourage.
A clinical chart review allowed the collection of clinical and la-
boratory data related to the disease history and severity; laboratory
parameters were collected as mean of last year's values. All data were
acquired between June 2016 and June 2017. Patients and healthy
subjects also participated to studies on cerebrovascular involvement
(Tartaglione et al., 2019) and on cognitive involvement.
(Tartaglione et al., 2019)
The study protocol was approved by the institutional review board
and written informed consent was obtained from each participant ac-
cording to the Declaration of Helsinki.
Neurological and cognitive evaluation
All subjects were briefly evaluated before brain MRI: gait, co-
ordination, speech, motor strength, main cranial nerves were assessed
and a rapid clinical interview investigated previous history of neuro-
logical dysfunction. Neurological impairment was an exclusion cri-
terion. Most study subjects (66/74 patients and 45/56 healthy controls)
underwent Intelligence Quotient (IQ) testing using the Wechsler Adult
Intelligence Scale-Fourth Edition (WAIS-IV)
Quantitative MRI
Whole brain data were acquired on the same 3T MRI scanner
(MAGNETOM Skyra, Siemens, Erlangen Germany) with a 20-channel
head coil. The qMRI imaging protocol consisted of three multi-echo 3D
FLASH sequences according to the multi-parametric mapping protocol
(Weiskopf and Helms, 2008), respectively with predominant T1-,
proton density-, and Magnetization Transfer-weighting (more details
Supplemental file 1). All the multi-parametric mapping sequences were
acquired at 1mm isotropic resolution. In addition to the multi-para-
metric mapping series, a 3D T1-weighted magnetization prepared rapid
gradient echo (MPRAGE) sequence (repetition-time=2400ms, echo-
time=2.25ms, resolution=1×1×1mm (Á et al., 2013), matrix-
size=256×256, anterior-posterior phase encoding direction, general-
ized autocalibrating partially parallel acquisition (GRAPPA) factor of 2
in phase-encoding direction) was also acquired for volumetric analyses.
The scan time was 26 min for each subject.
Iron content analysis
Quantitative whole brain R2* maps were estimated using SPM12
(www.fil.ion. ucl.ac.uk/spm) running on Matlab R2014a (The
MathWorks Inc., Natick, MA, USA) and the voxel-based quantification
batch tool (Draganski et al., 2011). The R2* value at each voxel was
estimated with the ESTATICS (estimating the apparent transverse re-
laxation time R2* from images with different contrasts) method which
is based on a linear regression on the logarithm of the signal intensities
of all echo images of all multi-parametric mapping series (PD, T1 and
MT multi-echo images) (Weiskopf et al., 2014). The Signal to Noise
(SNR) ratio was calculated as the ratio between the mean signal in-
tensity in the brain and the standard deviation of the noise in each echo
time for each contrast, to estimate the quality of the original acquired
images, and the root-mean-square error, was quantified at each voxel to
evaluate the goodness of the parameter fitting.
For the voxel-based quantification analysis, the Magnetization
Transfer maps were segmented into gray matter and white matter
probability maps using the unified segmentation approach
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(Ashburner and Friston, 2005) and the inter-subject registration (nor-
malization) was performed with the non-linear diffeomorphic algo-
rithm DARTEL (Ashburner, 2007). DARTEL normalization was then
applied to all iron-related (R2*) maps in combination with tissue-spe-
cific probability weighting and isotropic Gaussian smoothing (3mm full
width half maximum), as previously described (Draganski et al., 2011).
Besides DARTEL, a combined volumetric and surface normalization
(Postelnicu et al., 2009) was also applied to multi-parametric mapping
images to perform a different voxel-based quantification analysis
without tissue-specific probability weighting (and masking) and
without smoothing (Canna et al., 2018; Maldjian et al., 2003).
The hippocampal volume was calculated from the MPRAGE images
using the automated Freesurfer (https://surfer.nmr.mgh.harvard.edu/)
total reconstruction pipeline which consents the whole-brain segmen-
tation in a single-subject basis and the consequent extraction of several
structural brain metrics.
Statistical analysis
The between-group statistical comparisons of iron-related maps
were performed in SPM12 by fitting an analysis of covariance
(ANCOVA) linear model including age, sex and total intra-cranial vo-
lume of the subjects as covariates and running multiple post-hoc t-tests
on the fitted parameters, over all gray matter voxels. For the voxel-
based analysis a gray matter mask was used as previously suggested
(Callaghan et al., 2014) and family-wise error corrections for multiple
comparisons were applied using gaussian random field theory as im-
plemented in SPM12.
In addition to the voxel-based analysis, regional R2* values were
extracted for each participant in a priori regions of interest (ROIs) de-
fined in the putamen, globus pallidum, caudate nucleus and thalamus,
using the Harvard-Oxford subcortical standard atlas (https://fsl.fmrib.
ox.ac.uk/fsl/fslwiki/Atlases), and in red nucleus using the PickAtlas
Matlab toolbox (Postelnicu et al., 2009). ROI mean values were com-
pared between groups and linearly correlated with age in the three
groups of subjects. A posteriori ROIs were also defined based on the
results of the voxel-based analyses.
ROI-based ANCOVA analyses were also performed, and Pearson's
correlation coefficients were calculated, to respectively investigate the
differences in R2* values in relation to splenectomy and chelation
treatment including deferiprone (ongoing or previous treatment, three
and twenty-three TDT patients, respectively), and the correlation be-
tween R2* values and subjects’ age in all groups and structural (hip-
pocampal volume), and clinical (serum ferritin levels and LIC) findings
among patients. The analysis of cognitive data was restricted to the
patients for whom the data were available (i.e. missing cognitive data
were not extrapolated). Statistical thresholds were applied at p=0.05
after correction for multiple comparisons using the Bonferroni
method.
Data availability statement
Individual de-identified participant imaging data in DICOM format
will be shared upon request from other investigators for purposes of
replicating procedures and results. De-identified clinical and pre-pro-
cessed imaging data in NIFTI format, as well as accompanying docu-
ments describing the study protocol and the detailed procedures (soft-
ware codes) used in the statistical analysis, will be also shared upon
request from any qualified investigator.
All requests should be sent via email to the corresponding author
who will provide within three weeks a web link to a trusted data re-
pository together with detailed information for secure (password-pro-
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Results
Among 152 adult beta-thalassemia patients followed in the parti-
cipating sites 11 were excluded due to one of the exclusion criteria
listed above: contraindications to MRI (1 patient with implantable
cardioverter defibrillator, 6 with claustrophobia), history of head
trauma (1), history of neurologic disease (1 perinatal hypoxic ischemic
encephalopathy, 1 congenital viral infection, 1 stroke). Among the re-
maining 141 beta-thalassemia patients (all neurologically asympto-
matic and potentially recruitable), 62 did not participate because of
poor compliance (mostly because of excessive distance from the center
where MR-examinations were performed), 7 had excessive motion ar-
tifacts and 2 interrupted prematurely the exam.
Forty-seven transfusion dependent patients (TDT; mean-age:
36.9 ± 10.3 years, 63% females), 23 non-transfusion dependent pa-
tients (NTDT; mean-age: 29.2 ± 11.7 years, 56% females) and 57
healthy controls (HC; age: 33.9 ± 10.8 years, 65% females) were en-
rolled in the study. Patients subgroups and controls did not differ for
age and gender (p>0.5).
The main demographic and clinical characteristics of the beta-tha-
lassemia patients and controls are shown in Table 1. No patient or
control showed overt or silent territorial, hemodynamic or lacunar
stroke. Nineteen patients had history of HCV: 12/19 cleared after
therapy in 2015–2016. Serum ferritin levels of the 7/19 HCV+ TDT
patients did not differ from those observed in HCV- TDT patients.
Psychometrics
The overall assessment of cognitive function showed lower IQ va-
lues in beta-thalassemia patients compared to controls (76.0 ± 19.3
versus 97.8 ± 18.1 p<0.0001). The differences persisted after cor-
rection for education level. IQ values did not correlate with age and
showed no significant sex-related differences.
ROI-based analysis of iron-related (R2*) maps
In all a priori selected gray matter subcortical ROIs (putamen,
globus pallidum, caudate nucleus, thalamus, red nucleus) no significant
differences were found in the R2* values between TDT and NTDT pa-
tient subgroups (p>0.05, with or without correction for multiple
comparisons, see Table 2). In addition, no association was found be-
tween regional R2* values and splenectomy, and no significant corre-
lation was found with LIC values. Only the three patients under ongoing
chelation therapy with deferiprone showed lower-than-average R2*
values (Supplemental Figure 1). However, patients with a previous
history of deferiprone treatment (sixteen TDT patients in total, after
excluding the three patients with ongoing deferiprone treatment) did
not show significantly decreased R2* values compared to controls or to
patients who had never had deferiprone treatment. The slopes of the
estimated linear correlation between mean regional R2* values and age
are reported in Table 3 separately for each group.
Whole-brain analysis of iron-related (R2*) maps
The whole-brain voxel-based analysis of R2* parameter highlighted
a strong linear correlation with age (r2=0.51; p<0.05 family-wise
corrected for multiple comparisons) in deep subcortical structures, and
particularly in the putamina, both in controls and beta-thalassemia
patients (Fig. 1).
Compared to controls, the whole group of beta thalassemia patients
showed significantly higher R2* values in small symmetric clusters in
the anterior hippocampal formation and around the Luschka foramina
(i.e. posterior margin of the inferior cerebellar peduncle and anterior
margin of the cerebellar tonsils) (p<0.05 family-wise corrected for
multiple comparisons; Fig. 2a, Table 4). Comparing TDT subgroup and
controls, the R2* increase was even more evident with additional
symmetric clusters of difference appearing in the dorsal thalamic sur-
faces (p<0.05 family-wise corrected for multiple comparisons; Fig. 2b).
No significant differences were found between NTDT patients and
controls or between NTDT and TDT subgroups.
The whole-brain voxel-based analysis of R2* parameter restricted to
the whole group of beta thalassemia patients did not reveal any sig-
nificant correlation with serum ferritin levels over the entire gray
matter. Nonetheless, some positive linear correlations were descrip-
tively observed in two bilateral clusters (p<0.001, uncorrected), which
were overlapping with previous ROIs in anterior hippocampal forma-
tion, albeit located more towards the border of the gray matter, ad-
jacent to the choroid plexuses (Fig. 3).
A separate voxel-based quantification analysis of R2* maps was also
performed using combined volumetric and surface normalization in-
stead of DARTEL normalization. This alternative normalization proce-
dure did not include smoothing or masking of the ventricles harboring
the choroid plexuses and showed that iron accumulation was un-
ambiguously confined in the choroid plexuses (see Supplemental Figure
2).
The SNR was calculated for each echo of the MPM acquisitions and
it is shown for one representative healthy subject in the supplementary
figure 3(a). In general, higher SNR values were found in PD images
(min to max) 2.8 to 4.1, than in MT, 1.8 to 2.9 and T1 1.6 to 2.7 images.
To evaluate the resulting errors in R2* quantification, the root-mean-
square error from the fitting procedure across all voxels is shown in the
supplementary figure 3(b). The mean (± sd) root-mean-square error in
the gray and white matter was 0.05 (± 0.06) and 0.038 (± 0.02) re-
spectively.
Iron-related (R2*) maps, serum ferritin levels, cognitive assessment scores
and hippocampal formation volume
No significant correlation was found between R2* values of “a
priori” above-mentioned selected ROIs, or significant clusters from the
voxel-based analysis, and the cognitive assessment scores. All clusters of
Table 2
Mean± standard deviation of R2* values [s−1] across subjects.
HC [s−1] NTDT [s−1] TDT [s−1]
Left CN 16.86 ± 1.58 16.59 ±1.43 16.10 ± 1.68
Right CN 16.31 ± 1.79 15.92 ±1.31 15.59 ± 1.66
Left Put 15.10 ± 1.84 15.86 ±1.85 15.49 ± 2.60
Right Put 15.08 ± 2.05 15.49 ±1.73 15.33 ± 2.84
Left GP 19.74 ± 2.30 20.57 ±2.53 20.73 ± 3.29
Right GP 21.06 ± 2.48 21.89 ±2.25 21.97 ± 3.59
Left Thal 9.82 ± 0.69 9.91 ±0.79 10.16 ± 1.05
Right Thal 10.21 ± 0.75 10.31 ±0.85 10.63 ± 1.15
RN 20.16 ± 2.21 21.29 ±2.25 21.21 ± 2.78
Table 2. Mean± standard deviation of R2* values [s−1] across subjects in the three
groups in the bilateral subcortical region of interest (Caudate Nucleus (CN), Putamen
(Put), Globus Pallidum (GP), Thalamus (Thal) and Red Nucleus (RN)) after re-
gressing out the variability due to subject's age and sex.
Table 3
Slopes of linear correlation of R2* vs age.
HC NTDT TDT
Left CN 0.100 0.102 0.084
Right CN 0.046 0.139 0.161
Left Put 0.178 0.234 0.138
Right Put 0.005 0.048 0.031
Left GP 0.116 0.209 0.172
Right GP 0.088 0.099 0.077
Left Thal 0.074 0.141 0.157
Right Thal 0.182 0.228 0.146
RN 0.009 0.048 0.030
Table 3. Slopes of the linear fitting of the R2* mean regional values on subject's age,
separately for each group. Subcortical region of interest considered: Caudate Nucleus
(CN), Putamen (Put), Globus Pallidum (GP), Thalamus (Thal) and Red Nucleus
(RN).
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increased R2* values showed significant correlations with serum fer-
ritin levels. Hippocampal formation R2* values showed no correlations
with hippocampal volume; no significant differences were found com-
paring the bilateral hippocampal volume between HC and both TDT
and NTDT.
Discussion
The present quantitative MRI study on beta-thalassemia patients
identified a disease-related increase of iron content, only in small
symmetric structures. This increase was accentuated by regular blood
transfusion treatment. Nonetheless, altogether, the regional pattern of
brain iron accumulation outside the neural tissue and the relationships
with clinical and laboratory measures allowed interesting considera-
tions regarding iron-related brain involvement in beta-thalassemia that
will be discussed in the following sections.
Iron overload in the brain
So far, it has not been clarified whether or not the brain is a target
site for aberrant iron accumulation in beta-thalassemia. Iron accumu-
lation is a well-defined phenomenon in aging brain (Callaghan et al.,
2014; Draganski et al., 2011), chronic neural tissue inflammation
(Gillen et al., 2018), secondary neurodegeneration (Kuchcinski et al.,
2017) or genetically determined neurodegenerative diseases (Di Meo
and Tiranti, 2018) and it is associated with functional impairment in
non-thalassemic diseases (Ji et al., 2017). Beta-thalassemia patients
have been repeatedly shown to present poorer cognitive performances
compared to normal subjects (Elalfy et al., 2017; Monastero et al.,
2000) and have persistently high serum iron levels, raising major
Fig. 1. (a)Whole-brain correlation maps (p<0.05, family-wise error correction for multiple comparisons) of R2* vs. age in healthy subjects (left) and beta-tha-
lassemia patients (right). (b) Scatter plot and linear trends of R2* values vs. age in the significant clusters of the bilateral putamina.
Fig. 2. T-maps of group comparison displayed on a single-subject normalized magnetization transfer (MT) map. (a) TDT and NTDT patients vs. HC. (b) TDT patients
vs. HC. All maps are thresholded at p<0.05 after family-wise error correction for multiple comparisons.
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concerns about a possible iron-related brain involvement, especially in
later phases of disease. Metafratzi et al. (2001) were the first to in-
vestigate the brain of beta-thalassemia patients with 2D spin-echo MRI,
reporting abnormally increased iron content in putamina, caudate nu-
clei and motor and temporal cortices. Akhlaghpoor et al. (2012), using
an improved 2D fast gradient-echo sequence, reported iron abnormal-
ities only in the caudate nuclei and thalami. Successively, the analysis
was further upgraded with the use of 3D gradient-echo MRI but none of
previous regions was replicated and only midbrain red nuclei and the
choroid plexuses disclosed a significant increase of iron content com-
pared to healthy controls. (Qiu et al., 2014) Finally,
Hasiloglu et al. (2017) investigated intracranial iron accumulation with
susceptibility weighted MRI and, albeit neglecting the brain tissue and
focusing solely on the choroid plexuses, they showed an increased iron
content in transfusion-dependent patients that was linearly dependent
to ferritin serum levels. These largely contradictory findings most likely
depended on differences in sample sizes, patient characteristics and
treatments, as patients were recruited in different countries and un-
derwent different iron quantification MRI protocols. Moreover, all
previous studies focused on regionally specific effects (using different
criteria for region of interest definition) and none presented a whole-
brain voxel-level analysis of iron content maps without a priori as-
sumptions on the potentially involved regions. Thereby, these findings
have not defined if iron overload systemically occurs in the brain tissue
or it is just a plausible inference from evidence obtained in other organs
and tissues.
A first key-point of the present iron content quantitative MRI study
is the detection in a large healthy control sample of values strikingly
consistent with the available literature, in terms of both amount and
age-dependence within the deep gray matter (Callaghan et al., 2014;
Pirpamer et al., 2016; Aquino et al., 2009). These findings strongly
support the reliability of the quantitative MRI analysis even when ap-
plied in a clinical setting and pave the way for the subsequent discus-
sion.
A second key-point is that beta-thalassemia patients showed almost
identical findings, including and especially the strict age dependence, in
almost the entire brain regardless of blood transfusion treatment.
Therefore, our whole-brain voxel-based quantitative analysis points to
no specific disease-related iron accumulation in most of the regions
(e.g. putamen and red nuclei) that have been previously identified as
significantly vulnerable to persistently increased serum ferritin levels.
Actually, beta-thalassemia showed significant iron overload in small
symmetric supratentorial and infratentorial brain regions. At a first
glance, these findings seem to confirm that the brain is at least re-
gionally vulnerable to abnormally elevated iron levels, likewise the
liver, the heart or the endocrine glands. This perception might be re-
inforced by the direct correlation between iron content and transfusion
regimen, where the treatment-related iron intake adds to the en-
dogenous iron excess often in spite of an aggressive chelation treat-
ment. Nonetheless, brain areas of significant iron overload in beta-
thalassemia patients do not seem to share any developmental, meta-
bolic or functional characteristics but a strict anatomical contiguity
with the choroid plexuses. For example, the dorsal thalamic symmetric
Table 4
Statistically significant clusters characterization.




TDT and NTDT vs HC R-LUSC 12, −43, −45 100
L-LUSC −15, −39, −48 90
R-HIPP 25, −14, −15 182
L-HIPP −26, −16, −15 75
TDT vs HC R-LUSC 12, −43, −46 246
L-LUSC −15, −38, −47 266
R-HIPP 29, −20, −12 738
L-HIPP −30, −39, 0 703
R-THAL 2, −29, 8 83
L-THAL −8, −20, 18 64
Table 4. Characterization of the clusters where the R2* was found different between
groups (p<0.05 fwe corrected). No suprathreshold clusters were found comparing
NTDT vs HC and comparing TDT vs NTDT. The clusters were named for an easier
localization: R-LUSC and L-LUSC are the clusters around the right and left Luschka
foramina, R-HIPP and L-HIPP are the right and left clusters around the anterior
hippocampal formations and R-THAL and L-THAL are the clusters on the dorsal
thalamic surfaces.
Fig. 3. (a) Whole-brain correlation maps (p<0.001, uncorrected) of R2* vs. serum ferritin in both groups of beta-thalassemia patients. (b) Scatter plot, linear trends
and R2 values of R2* values vs. serum ferritin in the bilateral significant clusters.
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regions identified in the comparison between TDT patients and healthy
controls encompass several nuclei with different functional roles,
grouped together only by the fact that the choroid plexuses of the lat-
eral ventricles lay on them. Similarly, infratentorial regions were lim-
ited to symmetric small regions (namely the posterior aspect of the
inferior cerebellar peduncles and the superficial anterior medial portion
of the cerebellar tonsils) around the choroid plexuses of the IV ventricle
protruding in the subarachnoid spaces through the Luschka's foramina.
Finally, the most specific correlations between brain R2* values and
serum ferritin levels emerged closest to the border between the gray
matter and the choroid plexuses. As the choroid plexuses are known
from previous studies to be highly sensitive to iron accumulation
(Qiu et al., 2014; Hasiloglu et al., 2017), it is very likely that the ap-
parent iron content increase of nearby above-mentioned regions is
caused by the unavoidable smoothing implied by the volumetric nor-
malization applied to all quantitative R2* maps for the voxel-based
morphometric analysis.
More puzzling is the interpretation of iron overload within part of
the hippocampal formations. These regions share indeed common em-
bryological origin, development path, cortical structure, metabolic de-
mand and are homogeneously committed in a few brain functions such
as memory-related cognitive processes. As beta-thalassemia patients
often present with significantly increased rate of impaired cognitive
performances (Elalfy et al., 2017) and memory seems to be also in-
volved (Monastero et al., 2000), the hypothesis of a selective hippo-
campal formation involvement appears intriguing. At the same time,
along the entire superior-medial border of the hippocampal formation
runs a choroid plexus raising the suspicion of a possible artifactual
nature of the iron content increase. The latter hypothesis is supported
by the following facts: 1) the known direct correlation between blood
and choroid plexus iron levels, 2) the close anatomical adjacency be-
tween choroid plexuses and all the supratentorial and infratentorial
regions, 3) the lack of atrophy of the hippocampal formation even in the
more severe form of beta-thalassemia patients. On the other hand, even
the ascertained artifactual origin of the measurements does not exclude
the presence of a concomitant underlying iron overload in (part of) the
highlighted brain regions. As a matter of fact, according to our study it
is only possible to state that there is no evidence of increased iron
content in the neural tissue of the brain of beta-thalassemia patients
(regardless to transfusion treatment) and iron-related blooming arti-
facts due to plexuses overload are by far the best explanation of the
above-mentioned abnormal imaging findings. Only direct pathologic
investigations of these regions could be able to state the lack of iron
accumulation in brain tissues but the plexuses. As far as we know, the
only histopathology study describing iron content in the brain of five
TDT patients (Witzleben and Wyatt, 1961) reported as follows: “Central
nervous system. No stainable and very little chemical iron is present in the
parenchyma. Intense accumulations are present in the epithelium of the
choroid plexus and iron is also present in scattered mesenchymal elements in
the supporting tissues of the plexus.” To further confirm this interpreta-
tion, a second analysis was performed on the same data that avoids
smoothing and masking of the ventricles harboring the choroid
plexuses. This analysis also showed that iron accumulation is un-
ambiguously confined in the choroid plexuses sparing the contiguous
neural tissue.
Lastly, previous chelation treatment did not significantly affect
brain tissue iron content although an ongoing deferiprone was asso-
ciated with lower-than-normal brain tissue iron deposits in the only
three patients belonging to this small subgroup. Thus, if any, the effect
of deferiprone seems to be just a transient effect as any history of
previous treatment was not associated with persistently decreased iron
levels. Even though further validation is needed on larger series of
patients, as a whole these findings allow some interesting speculations.
First, as deferiprone is the sole chelation treatment able to pass the
blood-brain barrier, the latter appears to represent the main obstacle to
brain iron overload in conditions of serum iron excess. Secondly, the
applied MRI quantification protocol seems to be potentially sensitive to
treatment-related brain iron content changes thus confirming its effi-
ciency in detecting tissue iron levels. Finally, brain tissue homeostasis
mechanisms of beta thalassemia patients seem to be able to re-establish
the physiological iron content after the withdrawal of deferiprone, thus
suggesting the importance of brain iron content homeostasis.
Iron overload in the brain: comparison with the available literature
The present study did not confirm previous conflicting observations
regarding iron overload in the brain (Table 5). Discrepancies among
studies likely derived from limited sample size of previous studies due
to the disease rarity, different methodological approaches with regards
to both the MRI sequences and the subsequent analysis (ROI-based on
different image sections versus whole brain voxel-based analysis), pa-
tient characteristics and treatment differences (e.g. patients recruitment
in different countries employing different clinical programs). The pre-
sent study used (i) both a voxel-based approach in order to include
every brain region and an ROI-based approach to optimize the statis-
tical comparison, (ii) the most validated quantitative MRI protocol and
image analysis pipeline that well replicated normative values and aging
related trends in the literature (Callaghan et al., 2014), and (iii) an
adequate sample size of TDT patients with healthy controls but also
with a consistent group of NTDT patients in order to provide a more
detailed evaluation of the iron overload phenomenon in the brain.
According to our study, none of the previously recognized regions (but
those closer to choroid plexuses) showed increased iron load (Table 5).
Obviously, our data might represent the picture of patients treated
according to the current guidelines from the Thalassemia International
Federation (Cappellini et al., 2014). In Italy, for example, a mean he-
moglobin level of 9.5 g/dL is considered a reliable target of treatment,
while in other countries the level for transfusion is often set to lower
levels. Dietary and environmental factors together with the regimens of
chelation treatment might have also had an impact on the iron de-
position in the brain leading to normal values in all regions that showed
iron overload in at least one of the previous studies. As a whole, our
study seems to reveal a striking sparing of the neural tissue suggesting
that, with the current treatment protocols, iron overload might severely
affect several organs but not the brain. Whether this result is due to the
Table 5
'A priori' region of interest-based analysis.
Year Patients Age HC Put GP CN MC TC Thal RN ChP
Metafratzi et al. 2001 41 TDT 24 (8.5–44) 58 + – + + + n.e. n.e. n.e.
Akhlaghpoor et al. 2012 53 TM 25.9 ± 1.0 40 – – + n.e. n.e. + – n.e.
Qiu et al. 2014 31 TM 25.3 ± 5.9 33 – – – n.e. n.e. – + +
Hasiloglu et al. 2017 18 TDT (17 TM) 19 (7–39)* 18 n.e. n.e. n.e. n.e. n.e. n.e. n.e. +
Present study 2018 47 TDT 23 NTDT 36.9 ± 10.3 29.2 ± 11.7 56 – – – n.e. n.e.- – – +
Table 5: 'A priori' region of interest-based analysis of increased iron content in the brain parenchyma: literature and present study findings. *median-age and range;
TDT=transfusion dependent thalassemia; TM=thalassemia major; NTDT=not transfusion dependent thalassemia; HC=healthy controls; Put=putamen; GP=globus pal-
lidum; CN=caudate nucleus; MC=motor cortex; TC=temporal cortex; Thal=thalamus; RN=red nucleus; ChP=choroid plexuses; +=increased iron content; -=no iron
accumulation in patients; n.e.=not evaluated.
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presence of a blood brain barrier or to an efficient iron wash out system
in the brain cannot be unraveled, even though preliminary data on
ongoing deferiprone treatment seem to point to the role of the blood-
brain barrier. Notably, the sole autoptic study provided similar findings
(i.e. no iron excess in the brain but in the choroid plexuses) thus ex-
cluding the role of chelation treatments that were not available in the
early sixties (Witzleben and Wyatt, 1961). In any case, it seems that
imaging the brain in the search of iron overload in neurologically
asymptomatic patients treated with the current guideline is not sup-
ported by our analysis at least until the forth/fifth decade of life. Future
follow-up studies on ageing patients will prove if the concern about
iron-related brain injury is real or simply an incorrect inference of what
happens in the heart, liver and endocrine glands.
Iron overload in the brain: clinical implications
Neurological involvement in beta thalassemia has become more
evident with the considerable increase of life expectancy associated to
regular blood transfusion and chelation therapy. A major concern re-
gards cognition as several cognitive fields have been shown to be
variably compromised in beta-thalassemia patients (Elalfy et al., 2017).
Lower cognitive performances have been attributed to disease-related
chronic ischemia, to treatment side effects and to the high number of
hospitalizations occurring since the very first years of life
(Economou et al., 2006). Brain iron overload has been also included in
the list of possible mechanisms of brain injury due to its potential
neurotoxicity. Previous pioneering MRI studies have supported this
hypothetical pathogenic mechanism disclosing areas of iron overload in
the cortical and subcortical brain structures with a possible role in
neurocognition (Metafratzi et al., 2001; Akhlaghpoor et al., 2012). The
lack of evidence of neural tissue iron overload seems to curtail the
causal relationship between brain iron and cognitive impairment.
Nonetheless, even choroid plexus iron overload could be responsible of
neurodegeneration. The production of free radicals in the cerebrospinal
fluid or in tissues contiguous to regions strictly related to cognition
could be a potentially dangerous pathogenic mechanism, but the lack of
association between tissue iron levels and cognitive impairment in our
beta-thalassemia sample and the lack of relationship between iron le-
vels and the volume of the hippocampal formations make this hy-
pothetical relationship rather unlikely. Therefore, according to our
study, the main cause of cognitive impairment in beta-thalassemia
should not be searched in iron dysmetabolism.
Limits of the study
Even though this multicenter study investigated with MRI the lar-
gest beta-thalassemia sample so far, the rarity of the disease allowed the
recruitment of limited dozens of patients (47 TDT and 23 NTDT pa-
tients). The NTDT sample size might appear relatively small for firm
conclusions in this subgroup. However, among beta-thalassemia pa-
tients, TDT ones typically present the most severe systemic iron over-
load due to blood transfusion treatment. The lack of neural tissue iron
overload in the TDT subgroup points to an unlikely or scarce brain
involvement in the whole disease phenotypic spectrum. Larger studies
might help to refine our results even though the detection of additional
areas of iron overload requiring larger series would likely have a lim-
ited clinical impact.
From a methodologic point of view, R2* might depend on other
factors besides iron content, including cellularity and water content.
However, there is no data about changes of these possible confounders
both from histopathology and conventional MRI. In addition, although
high resolution imaging makes the R2* closer to R2 measurements, R2
might outperform R2* if the iron stores are primarily ferritin, not he-
mosiderin, thus preventing firm conclusions from the present study.
However, the fact that the histopathology of five TDT patients did not
reveal significant iron increase in the brain except than in the choroid
plexuses strongly support our findings (Witzleben and Wyatt, 1961).
Finally, this study was conducted in a world region with treatment
guidelines that are relatively conservative in terms of hemoglobin levels
to be maintained and that include homogeneous indications for chela-
tion treatment. Therefore, our results cannot be generalized to other
areas of the world where transfusion regimens are regulated by lower
hemoglobin levels and where chelation guidelines might be different or
dependent from chelation treatment availability. Nonetheless, this
study shows that, with the current beta-thalassemia treatment guide-
lines, there is no evidence of brain tissue iron overload but in the
choroid plexuses limiting any indication in beta-thalassemia patients to
follow-up brain iron content with dedicated, time consuming brain MRI
protocols.
Conclusion
Even though iron poisoning is detrimental in several organs and
represent a life-threatening condition in beta-thalassemia, its occur-
rence in the brain neural tissue might be a far more limited and cir-
cumscribed phenomenon, at least in patients undergoing conservative
guidelines of treatment. In fact, brain iron overload seems to be con-
fined in the choroid plexuses and its detection in the neural tissue
(including the hippocampal formations) seems to be attributable to a
blooming effect. According to study evidence, literature review and
previous autoptic findings, routine monitoring of parenchymal iron
overload in the brain of beta-thalassemia patients is likely not required.
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